BioAMB
A Breakthrough Amphotericin-B Therapy
BioAMB is a next-generation amphotericin-B (AMB) variant designed to overcome the major safety and tolerability limitations of conventional AMB therapies.
Unlike typical reformulations, BioAMB is a novel bio-drug entity that releases AMB as the active agent, combining high efficacy with improved patient safety and ease of use.
Key Advantages of BioAMB
- Reduced kidney toxicity and improved patient tolerance
- Simple injection instead of intravenous infusion
- Optimized frequency and duration of therapy
Unmet Clinical Need
Invasive fungal infections are a significant threat for immunocompromised patients, and resistance to azoles — a first-line antifungal class — is steadily increasing.
Amphotericin-B remains one of the few effective therapies for life-threatening infections, including aspergillosis.
However, current AMB formulations are associated with severe toxicity that limits their use and tolerability.
BioAMB aims to change this landscape by delivering the proven efficacy of AMB with a dramatically improved safety profile, enabling broader and earlier use in critical care.
Market Opportunity
- 4 million people affected by aspergillosis worldwide
- Annual $600M global market for AMB formulations
- High unmet need for safer, more effective antifungal therapies
- BioAMB has the potential to become a first-line therapy, expanding treatment reach and improving patient outcomes.
Strategic Positioning
ImmuPharma is advancing BioAMB as part of its anti-infective program, addressing urgent global health priorities.
Our approach is built on:
- Targeting high-burden, high-resistance pathogens,
- Developing novel, differentiated drug entities,
- Delivering clinical and economic value for patients and healthcare systems.
BioAMB: unlocking the full potential of amphotericin-B — with safety, simplicity, and strength.
